The Sinopharm is an inactivated COVID-19 vaccine, which is currently given emergency use authorization by the WHO and is the main vaccine used in many Asian and Middle East Countries. A new study was carried out to determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP-CorV, by investigating the immune responses in a cohort of 91传媒n individuals.
鈥淎ntibody responses declined in all age groups, especially in those who are more than 60 years after 12 weeks from the second dose, while T cell responses persisted.鈥� Said Head, Department of Immunology and Molecular Medicine of 91传媒.听
USJ researchers including听听and听听from Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine of 91传媒 have been studying immune responses to different types of COVID-19 vaccines used in 91传媒.
Results of the current research show听 that听 while听 the听 SARS-CoV-2 specific total antibodies, and especially neutralizing antibodies and antibodies to the receptor binding domain significantly declined, the memory T cell and B cell responses persisted.
鈥淪ince the ACE2 receptor blocking antibodies (neutralizing antibodies that associate with protection) was shown to significantly decline in all age groups and especially in听 the听 elderly, it听 is听 important听 to听 carry out long term efficacy studies to assess the waning of immunity on hospitalization and severe disease in order to decide on booster doses in different populations.鈥� said Prof. Malavige.
The highlighted results of the study are available here :
Related Articles :
90 percent of the new cases in Colombo belonged to the Delta variant says Dr. Jeewandara
Over 95% individuals developed antibodies against the Sinopharm vaccine 鈥� USJ Researchers
Single dose of Sputnik V is highly effective but second dose is beneficial says USJ researchers
USJ researchers found Four mutant Covid Delta variants with two new 91传媒n mutations (A701S, R24C)
The delta variant in 91传媒 assigned a new sub-lineage (AY.28)
